Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.51 |
| ▸ | ERN1 | O75460 | 3/20 | 0.47 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.38 |
| ▸ | ALPL | P05186 | 4/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | KDR | P35968 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.35 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.35 |
| ▸ | PRKDC | P78527 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29377196 | 1.00 | PTGDR2 (0.51) | PTGDR2ERN1MAOAMAOBCYP2A6 | |
| SCHEMBL2535068 | 0.86 | PTGDR2 (0.43) | PTGDR2ERN1MAOAMAOBALPL | |
| SCHEMBL207935 | 0.86 | MAOA (0.52) | PTGDR2ERN1MAOAMAOBCYP2A6 | |
| SCHEMBL12225949 | 0.84 | PTGDR2 (0.44) | PTGDR2ERN1MAOAMAOBALDH1A1 | |
| SCHEMBL16955034 | 0.82 | MAOA (0.43) | PTGDR2ERN1MAOAMAOBALPL | |
| SCHEMBL16953938 | 0.82 | MAOA (0.40) | PTGDR2MAOAMAOBALPLTDP1 | |
| SCHEMBL6500895 | 0.80 | GPR3 (0.42) | ERN1ALDH1A1MAPK1EPHX2POLB | |
| SCHEMBL27391967 | 0.79 | EPHX2 (0.33) | PTGDR2TDP1ALDH1A1EPHX2TSHR | |
| SCHEMBL2534007 | 0.79 | PTGDR2 (0.49) | PTGDR2MAOAMAOBALDH1A1PTPN1 | |
| SCHEMBL21266933 | 0.79 | ALDH1A1 (0.41) | ERN1CYP2A6TDP1ALDH1A1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3558298-B1 | ANTIDIABETIC SPIROCHROMAN COMPOUNDS | MERCK SHARP & DOHME LLC (US) | 2026-03-11 | — | — | EP | disclosed |
| US-20250223281-A1 | ANTIDIABETIC COMPOUNDS AND COMPOSITIONS | REZUBIO PHARMACEUTICALS CO., LTD (CN) | 2025-07-10 | — | — | US | disclosed |
| US-20250214951-A1 | 3-PHENYLISOXAZOLE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING EYE DISEASE, CONTAINING SAME AS ACTIVE INGREDIENT | VASTHERA CO., LTD. (KR) | 2025-07-03 | — | — | US | disclosed |
| US-20250073338-A1 | CONJUGATE COMPOUNDS AND COMPOSITIONS | REZUBIO PHARMACEUTICALS CO., LTD (CN) | 2025-03-06 | — | — | US | disclosed |
| US-20240002354-A1 | ANTIDIABETIC COMPOUNDS AND COMPOSITIONS | REZUBIO PHARMACEUTICALS CO., LTD (CN) | 2024-01-04 | — | — | US | disclosed |
| WO-2023182871-A1 | 3-PHENYLISOXAZOLE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING EYE DISEASE, CONTAINING SAME AS ACTIVE INGREDIENT | 바스테라 주식회사 | 2023-09-28 | — | — | WO | disclosed |
| CN-116472273-A | Antidiabetic compounds and compositions | 宁康瑞珠生物制药(珠海)有限公司 | 2023-07-21 | — | — | CN | disclosed |
| US-10968232-B2 | Antidiabetic spirochroman compounds | MERCK SHARP & DOHME CORP. (US) | 2021-04-06 | — | — | US | disclosed |
| US-20190337961-A1 | ANTIDIABETIC SPIROCHROMAN COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2019-11-07 | — | — | US | disclosed |
| EP-3558298-A1 | ANTIDIABETIC SPIROCHROMAN COMPOUNDS | Merck Sharp & Dohme Corp. (US) | 2019-10-30 | — | — | EP | disclosed |
| US-20110275515-A1 | CYCLOPENTADIONE DERIVED HERBICIDES | SYNGENTA CROP PROTECTION, LLC (US) | 2011-11-10 | — | — | US | disclosed |
| US-D646956-S1 | TV mount | LEUNG ALEX | 2011-10-18 | — | — | US | disclosed |
| WO-2010136431-A9 | SPIRO EPOXIDES AS INTERMEDIATES | SYNGENTA LIMITED (GB) | 2011-03-10 | — | — | WO | disclosed |
| WO-2010136431-A1 | SPIRO EPOXIDES AS INTERMEDIATES | SYNGENTA LIMITED (GB) | 2010-12-02 | — | — | WO | disclosed |
| WO-2010102848-A1 | CYCLOPENTADIONE DERIVED HERBICIDES | SYNGENTA LIMITED (GB) | 2010-09-16 | — | — | WO | disclosed |
| WO-2010081894-A1 | CYCLOPENTADIONE DERIVED HERBICIDES | SYNGENTA LIMITED (GB) | 2010-07-22 | — | — | WO | disclosed |
| WO-2010081755-A1 | NOVEL HERBICIDES | SYNGENTA LIMITED (GB) | 2010-07-22 | — | — | WO | disclosed |
| EP-1910292-A1 | PIPERIDINE DERIVATIVE AS TACHYKININ RECEPTOR ANTAGONIST | Takeda Pharmaceutical Company Limited (JP) | 2008-04-16 | — | — | EP | disclosed |
| US-20070149570-A1 | Piperidine derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-06-28 | — | — | US | disclosed |
| WO-2007015588-A1 | PIPERIDINE DERIVATIVE AS TACHYKININ RECEPTOR ANTAGONIST | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149570-A1 | Piperidine derivative and use thereof | TACR1, OPRL1, TRPV1 | PTGDR2 41/4885ERN1 4124/4885MAOA 760/4885 |
| US-10968232-B2 | Antidiabetic spirochroman compounds | GPR119, GPR52, GPR55 | PTGDR2 405/4885ERN1 2413/4885MAOA 4541/4885 |
| US-20190337961-A1 | ANTIDIABETIC SPIROCHROMAN COMPOUNDS | GPR119, GPR52, GPR55 | PTGDR2 405/4885ERN1 2413/4885MAOA 4541/4885 |
| US-20250223281-A1 | ANTIDIABETIC COMPOUNDS AND COMPOSITIONS | GPR119, GLP1R, GPR65 | PTGDR2 370/4885ERN1 2622/4885MAOA 4332/4885 |
| US-20110275515-A1 | CYCLOPENTADIONE DERIVED HERBICIDES | DDT, CYP1B1, CYP1A1 | PTGDR2 1683/4885ERN1 4033/4885MAOA 1805/4885 |
| US-20250073338-A1 | CONJUGATE COMPOUNDS AND COMPOSITIONS | GPR119, GPR65, GPR55 | PTGDR2 261/4885ERN1 4163/4885MAOA 4007/4885 |
| US-20250214951-A1 | 3-PHENYLISOXAZOLE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING EYE DISEASE, CONTAINING SAME AS ACTIVE INGREDIENT | ATG7, BECN1, MAP1LC3B | PTGDR2 258/4885ERN1 3296/4885MAOA 1043/4885 |
| US-20240002354-A1 | ANTIDIABETIC COMPOUNDS AND COMPOSITIONS | GPR119, GLP1R, GPR65 | PTGDR2 405/4885ERN1 2637/4885MAOA 4425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.